Literature DB >> 21632605

Effect of a small priming dose on myoclonic movements after intravenous anaesthesia induction with Etomidate-Lipuro in children.

Y Nyman1, K von Hofsten, C Ritzmo, S Eksborg, P A Lönnqvist.   

Abstract

BACKGROUND: In children, the incidence of injection pain at i.v. anaesthetic induction with Etomidate-Lipuro is low when compared with propofol mixed with lidocaine (5%). However, the incidence of involuntary myoclonic movements (MM) after induction of anaesthesia is higher compared with propofol (85% vs. 15%). In adults, the incidence of MM is reported to be significantly reduced if a small priming dose is administered immediately before the main injection of etomidate. The aim of this prospective, randomized, double-blind, placebo-controlled clinical trial was to investigate if a small priming dose of etomidate effectively can reduce the incidence of MM also in children.
METHODS: Eighty ASA I-II children (1-15 yr) were randomized to receive either a small priming dose of etomidate (0.03 mg kg(-1)) or a lipid emulsion placebo. A standardized induction dose of etomidate (0.3 mg kg(-1)) was administered 60 s after the priming dose. The occurrence and severity (observational score 0-3) of MM was defined as the primary endpoint of the study and was recorded during a 2 min period after induction of anaesthesia. A post hoc analysis was performed regarding the incidence of MM with respect to age.
RESULTS: No difference in the occurrence or severity of MM was found between the two study groups, the total incidence of MM being 73.8% (95% confidence interval: 62.7-83.0%). The incidence of MM (score > 0) was found to be statistically higher in the age group 5-10 yr compared with <5 yr; and >10 yr (P=0.0008 and 0.01730, respectively). The MM scores were highest in patients aged 5-10 yr (P=0.0021).
CONCLUSIONS: Children in the age range of 5-10 yr appear to be especially prone to react with involuntary MM after i.v. induction of anaesthesia with etomidate. The use of a small, non-sedative, priming dose did not influence the incidence of involuntary MM after i.v. induction of anaesthesia with etomidate in children 1-15 yr of age.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632605     DOI: 10.1093/bja/aer129

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  6 in total

1.  Pretreatment with Oxycodone Simultaneously Reduces Etomidate-Induced Myoclonus and Rocuronium-Induced Withdrawal Movements During Rapid-Sequence Induction.

Authors:  Xiaoxia An; Caixia Li; Zayd Sahebally; Xiaohong Wen; Bing Zhao; Xiangming Fang
Journal:  Med Sci Monit       Date:  2017-10-19

2.  Effects of transcutaneous acupoint electrical stimulation combined with low-dose sufentanil pretreatment on the incidence and severity of etomidate-induced myoclonus: A randomized controlled trial.

Authors:  Ya Lv; Haijuan He; Junjie Xie; WenJun Jin; CanJi Shou; Yuanyuan Pan; Leilei Wang; Yunchang Mo; Qinxue Dai; Wujun Geng; Junlu Wang
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

3.  Polymorphisms of pharmacogenetic candidate genes affect etomidate anesthesia susceptibility.

Authors:  Lulin Ma; Yan Huang; Shiqian Huang; Feng Xu; Yafeng Wang; Shuai Zhao; Daling Deng; Yuanyuan Ding; Tianhao Zhang; Wenjing Zhao; Xiangdong Chen
Journal:  Front Genet       Date:  2022-09-28       Impact factor: 4.772

4.  Comparative study evaluating efficacy of sufentanil versus midazolam in preventing myoclonic movements following etomidate.

Authors:  Mohammad Alipour; Masoumeh Tabari; Azadeh Mokhtari Azad
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2016 Jan-Mar

Review 5.  Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics.

Authors:  Beatrijs I Valk; Michel M R F Struys
Journal:  Clin Pharmacokinet       Date:  2021-06-01       Impact factor: 6.447

6.  Clinical observation of the combined use of propofol and etomidate in painless gastroscopy.

Authors:  Lina Hao; Xibei Hu; Bingqing Zhu; Wanhong Li; Xiang Huang; Fang Kang
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.